Hyaluronic Acid and its derivatives
Your views are sought on the commissioning statement about hyaluronic acid and its derivatives. Local CCGs do not routinely commission or fund the peri-articular or intra-articular use of hyaluronic acid and its derivatives for the treatment of osteoarthritis and other joint conditions.
The CCG will only fund interventions that are supported by evidence that demonstrates clinical and cost effectiveness. At this time there is insufficient high quality evidence that demonstrates the clinical and cost effectiveness of hyaluronic acid and its derivatives.
This is an updated version of an existing commissioning position we would like your views on this. The consultation will close on Tuesday 28th August.
Please send comments to email@example.com or comment below.
Draft commissioning statement: Hyaluronic Acid and its derivatives